Product image of Imatinib Krka D.D. (Imatinib) supplied by GNH India

Imatinib Krka D.D.

Active Ingredient:
Imatinib
Origin:
EU

Imatinib Krka D.D. (Imatinib)

Imatinib, the active ingredient in Imatinib Krka D.D., is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is used to treat chronic myeloid leukemia and gastrointestinal stromal tumors in adult patients and is administered under medical supervision in specialized oncology settings.

GNH India supplies Imatinib Krka D.D. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Imatinib acts on specific tyrosine kinase‑driven malignancies, providing targeted therapy for several cancers.
  • Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces cytogenetic remission.
  • Gastrointestinal stromal tumor (GIST): inhibits tumor growth and improves progression‑free survival.
  • Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control when combined with chemotherapy.

How It Works

  • Imatinib selectively binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blockade halts signaling pathways that drive cell proliferation, survival and migration, leading to apoptosis of malignant cells that depend on these kinases. By maintaining the kinase in an inactive conformation, imatinib also reduces angiogenic factor release and impairs the tumor microenvironment.

Side Effects

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Edema: swelling of the hands, feet or periorbital area.
  • Fatigue: persistent tiredness affecting daily activities.
  • Diarrhea: loose stools that may require hydration.

Serious or Rare Side Effects

  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Severe neutropenia: marked reduction in white blood cells.
  • Cardiac failure: reduced heart function or congestive symptoms.

Precautions & Warnings

When prescribing imatinib, clinicians should observe several safety measures to minimize risk.

  • Monitor blood counts: perform regular complete blood count tests to detect cytopenias.
  • Assess liver function: check hepatic enzymes before and during therapy.
  • Evaluate cardiac status: baseline and periodic echocardiograms for patients with cardiac history.
  • Avoid use in pregnancy unless benefits outweigh risks: discuss potential fetal effects with the patient.
  • Store at room temperature: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise imatinib levels and toxicity.
  • CYP3A4 inducers (e.g., rifampin): can lower drug exposure and reduce efficacy.
  • Co‑administration with other tyrosine kinase inhibitors: increases risk of overlapping toxicities.

Moderate Interactions (Monitor Closely)

  • Warfarin: imatinib may affect INR, requiring closer anticoagulation monitoring.
  • Diuretics: may exacerbate fluid retention and edema, necessitating dose adjustments.

Frequently Asked Questions

Imatinib Krka D.D. is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia, gastrointestinal stromal tumor, and Philadelphia chromosome‑positive acute lymphoblastic leukemia. It targets specific molecular pathways that drive the growth of these cancers, helping to control disease progression.

Imatinib works by binding to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. This blocks phosphorylation of downstream signaling proteins, halting cell proliferation and survival signals that are essential for the growth of certain cancer cells.

The dose of Imatinib Krka D.D. is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. No fixed dosing regimen is provided here; the prescriber sets the appropriate regimen.

The safety of Imatinib in pregnancy and lactation is not well established. It is classified as pregnancy category unknown, and potential risks to the fetus or infant cannot be ruled out. Use only if the potential benefit justifies the potential risk, and discuss options with a healthcare professional.

To order Imatinib Krka D.D., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first targeted therapy approved for chronic myeloid leukemia and remains a standard first‑line option. Compared with newer tyrosine kinase inhibitors, it has a well‑characterized safety profile and long‑term efficacy data, though some newer agents may offer faster molecular responses in certain patient subsets.

Imatinib Krka D.D. should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain potency throughout its shelf life.

Imatinib Krka D.D. is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to ensure consistent absorption.

Serious risks include hepatotoxicity, severe neutropenia or other blood dyscrasias, and cardiac failure. Patients should be monitored regularly for liver enzyme elevations, blood count changes, and signs of heart dysfunction, and any concerning symptoms should be reported promptly to a healthcare professional.

Imatinib should be avoided in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant or breastfeeding unless the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Imatinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT